TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01839201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No psychological intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No psychological intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No psychological intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suggestion
Description: In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suggestion
Description: In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suggestion
Description: In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dreamfilm
Description: In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dreamfilm
Description: In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
Study: NCT00605059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]AV94
Description: Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Study: NCT04461353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerolized Hydroxychloroquine Sulfate
Description: sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
Study: NCT02509273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study: NCT01839201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dreamfilm
Description: In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
Study: NCT04105569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-Induced Biofilm Overgrowth
Description: Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
Study: NCT00764478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: asenapine tablet, 5 mg sublingually BID for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: asenapine tablet, 10 mg sublingually BID for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sublingual tablet, administered BID for 21 days
Study: NCT02029495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered via subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via subcutaneous injection until week 24.
Study: NCT03335618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitoring and Symptom Coaching
Description: Triggered check-ins by study personnel to keep participants on track to meet fitness goals

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Activity Monitoring
Description: Passive step tracking without check-ins
Study: NCT03603834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles
Study: NCT02103452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian and endometrial samples
Description: Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian and endometrial samples
Description: Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
Study: NCT02555657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Study: NCT02435550

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
Study: NCT05792748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulp hemostasis with a dry cotton pellet
Description: Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulp hemostasis with a wet cotton pellet impregnated with FS
Description: Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: Stainless steel crown placed as a final restoration
Study: NCT02435550

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
Study: NCT03665428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAMB treatment (modified quadruple therapy)
Description: Randomly assign either as PAMB or PBMT group treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PBMT treatment (bismuth-containing quadruple therapy)
Description: Randomly assign either as PAMB or PBMT group treatment
Study: NCT03411057

Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: An interactive form of meditation that includes gentle yoga.

Intervention type: OTHER
Intervention: Control
Description: Standard of care including an educational video.
Study: NCT00843843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light box
Description: Bright light of about 5000 lux, administered while sitting at a desk.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light box
Description: Bright light of about 5000 lux, administered while sitting at a desk.
Study: NCT03463096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High G acceleration on a long-arm human centrifuge
Description: Gx (chest-to-back) and Gz (head-to-toe)
Study: NCT01609179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
Study: NCT04540081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epic Healthy Planet Population Health Module
Description: Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
Study: NCT02207556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use.
Study: NCT03011450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877
Study: NCT05792748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: Stainless steel crown placed as a final restoration
Study: NCT03101319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol
Description: As mentioned in the description of the study arm
Study: NCT03011450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for K-877)
Study: NCT02756975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial prostate biopsy
Description: In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noncoaxial prostate biopsy
Description: In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing
Study: NCT03101319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B Complex Oral Tablet
Description: As mentioned in the description of the study arm
Study: NCT04217109

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Odour sampling
Description: Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample.
Study: NCT01303445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aggrenox alone
Description: Aggrenox 1 capsule twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox and omeprazole
Description: Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox and omeprazole
Description: Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole alone
Description: omeprazole 80 once daily for 7 days
Study: NCT01247064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized 3% saline
Description: 4 mL of nebulized 3% saline once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% Normal Saline
Description: 4 mL of 0.9% nebulized normal saline once
Study: NCT00947635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention - supplements
Description: Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention - supplements
Description: Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention - supplements
Description: Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
Study: NCT00924807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate, Bicalutamide, Sorafenib
Description: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
Study: NCT02381626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Log-book
Description: PM and biological measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
Study: NCT03848169

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency
Description: See previous page

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: See previous page
Study: NCT00292188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02010788

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
Study: NCT01408628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Insulin Education
Description: Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm.
Study: NCT03132194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPSG 7.5%
Description: topical gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aczone
Description: topical gel
Study: NCT00977158

Intervention type: PROCEDURE
Intervention: Throat Swab
Description: Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
Study: NCT01871324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: group therapy
Study: NCT02509273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT00985023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steel screw fixation of Lisfranc fracture-dislocation.
Description: Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
Study: NCT04192305

Intervention type: PROCEDURE
Intervention: LPV
Description: LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.

Intervention type: PROCEDURE
Intervention: routine LV
Description: Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
Study: NCT03132194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical gel
Study: NCT05011630

Intervention type: OTHER
Intervention: Pancreaticoduodenectomy
Description: The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA

Intervention type: OTHER
Intervention: Pancreaticoduodenectomy
Description: The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
Study: NCT01727882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief feedback
Description: A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily assessments
Description: Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
Study: NCT02617771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
Study: NCT01727882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily assessments
Description: Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
Study: NCT04667260

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maxillary sinus membrane elevation
Description: Maxillary sinus membrane elevation with blood coagulum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus membrane elevation
Description: Maxillary sinus membrane elevation with blood coagulum

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
Study: NCT00914459

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moroctocog alfa ( AF-CC)
Description: Dosing is at the discretion of the Investigator

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laboratory tests
Description: Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody